Mode
Text Size
Log in / Sign up

Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy aloneAdding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Neoadjuvant chemoradiation improves resection and survival for esophageal squamous cell carcinoma without increasing safety risks compared to chemotherapy alone.

A comprehensive meta-analysis evaluated 2,174 patients with esophageal cancer to compare neoadjuvant chemoradiation against chemotherapy alone. The study specifically examined outcomes for squamous cell carcinoma and adenocarcinoma subtypes across multiple clinical endpoints. Results indicated distinct benefits depending on the histological type of the tumor.

For squamous cell carcinoma, adding radiation therapy led to significantly higher resection rates and improved three-year overall survival. Patients also experienced fewer local recurrences when treated with the combined modality approach. The odds ratios strongly favored the chemoradiation strategy for this specific cancer subtype.

In contrast, adenocarcinoma patients showed similar outcomes regarding resection and survival regardless of the treatment method. However, the data suggested a trend toward more R0 resections with chemoradiation. Safety profiles remained comparable between groups, with no increase in anastomotic leaks observed.

The findings support tailoring neoadjuvant strategies based on tumor histology. Clinicians should consider chemoradiation for squamous cell cases to maximize surgical success and long-term survival. Further research is needed to confirm these benefits in broader populations.

Doctors looked at many studies involving over 2,000 patients with esophageal cancer. These patients received either chemotherapy alone or chemotherapy combined with radiation before surgery. The goal was to see if adding radiation made surgery safer or more effective.

For patients with squamous cell cancer, adding radiation made it much more likely that doctors could remove the entire tumor. It also helped clear the cancer completely inside the tissue in many cases. This group also had fewer chances of the cancer returning near the original site.

For patients with adenocarcinoma, adding radiation helped doctors remove the tumor more often. However, it did not change the risk of leaks at the surgical connection site. Overall survival improved for the squamous cell group but stayed the same for the adenocarcinoma group.

The study followed patients for about three years. While adding radiation helped some groups, it did not help all patients in the same way. Doctors must talk with patients to decide if this extra treatment is right for their specific type of cancer.

What this means for you:
Adding radiation to chemotherapy before surgery helped remove more tumors and lower local recurrence for some esophageal cancer types.

Study Details

Study typeMeta analysis
Sample sizen = 2,174
EvidenceLevel 1
Follow-up36.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: The benefit of neoadjuvant radiation for esophageal squamous cell carcinoma (SCC) and adenocarcinoma (AC) remains controversial. This study comprised a histology-stratified pooled analysis of randomized controlled trials (RCTs) comparing neoadjuvant chemoradiation (nCRT) to neoadjuvant chemotherapy alone (nCT) for esophageal cancer. METHODS: A PRISMA 2020-compliant systematic review for RCTs comparing nCRT to nCT for esophageal cancer and a histology-stratified pooled random-effects meta-analyses were performed. RESULTS: Nine RCTs published from 2009 to 2024 were included, comprising 2174 patients (1083 nCRT, 1091 nCT). Of these, 1125 patients had AC (51.7%) and 1049 had SCC (48.3%). Most patients received cisplatin with 5-fluorouracil. Patients with SCC undergoing nCRT were more often resected (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.05-3.60; P=0.03) and more often had a pathologic complete response (OR 8.78; 95% CI 3.27-23.57; P<0.0001) than those undergoing nCT; R0 resection rates (OR 2.18; 95% CI 0.81-5.9; P=0.12) and anastomotic leaks (OR 0.91; 95% CI 0.55-1.49; P=0.70) were similar. For AC, nCRT was associated with similar resection rates (OR 0.90; 95% CI 0.49-1.64; P=0.72), similar pathologic complete response (OR 2.77; 95% CI 0.84-9.21; P=0.10), more R0 resections (OR 2.94; 95% CI 1.51-5.74; P=0.002), and similar leak rates (OR 1.10; 95% CI 0.71-1.70; P=0.67). nCRT was associated with fewer local recurrences for SCC (OR 0.58; 95% CI 0.40-0.86; P=0.006) but not AC (OR 1.04; 95% CI 0.70-1.53; P=0.86) (subgroup test P=0.04) and improved 3-year overall survival for SCC (OR 1.51; 95% CI 1.16-1.96; P=0.002) but not AC (OR 0.81; 95% CI 0.60-1.10; P=0.18) (subgroup test P=0.002). CONCLUSIONS: Neoadjuvant radiation appears to confer meaningful improvement in long-term outcomes for SCC but not AC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.